The Summer 2008 issue of Olswang's Life Sciences Newsletter is now out. You can access it here. Highlights include the following morsels:
If you'd like to sign up to receive these Newsletters on a regular basis, email Jeremy here and he'll see that you are added to the circulation list.• Generics v Lundbeck, in which Lord Hoffmann sat in the Court of Appeal for England and Wales and gave the leading opinion regarding the concept of Biogen insufficiency in patent law;
• Conor v Angiotech, a House of Lords decision concerning taxol-coated coronary stents in which Lord Hoffmann also gave the leading opinion.
Recent publication
Reviewed by Jeremy
on
Friday, September 19, 2008
Rating:
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html